Phase I, open-label ascending dose trial of anti-CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti-PD-1/PD-L1 therapy

B. A. Wilky; P. Kumthekar; R. Wesolowski; J. J. Hwang; S. I. Park; G. Yuan; C. D. Dupont; M. Lim; O. Shebanova; J. M. Cuillerot; E. Dow; W. Ortuzar; Jeffrey J Raizer; E. Drouin; N. Wilson; A. M. Gonzalez; J. M. Goldberg; J. S. Buell; R. B. Stein; H. Youssoufian

doi:10.1093/annonc/mdy288.040

Phase I, open-label ascending dose trial of anti-CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti-PD-1/PD-L1 therapy

B. A. Wilky, P. Kumthekar, R. Wesolowski, J. J. Hwang, S. I. Park, G. Yuan, C. D. Dupont, M. Lim, O. Shebanova, J. M. Cuillerot, E. Dow, W. Ortuzar, Jeffrey J Raizer, E. Drouin, N. Wilson, A. M. Gonzalez, J. M. Goldberg, J. S. Buell, R. B. Stein, H. Youssoufian

Neurology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	viii416-viii417
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy288.040
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy288.040

Cite this

Wilky, B. A., Kumthekar, P., Wesolowski, R., Hwang, J. J., Park, S. I., Yuan, G., Dupont, C. D., Lim, M., Shebanova, O., Cuillerot, J. M., Dow, E., Ortuzar, W., Raizer, J. J., Drouin, E., Wilson, N., Gonzalez, A. M., Goldberg, J. M., Buell, J. S., Stein, R. B., & Youssoufian, H. (2018). Phase I, open-label ascending dose trial of anti-CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti-PD-1/PD-L1 therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii416-viii417. https://doi.org/10.1093/annonc/mdy288.040

Wilky, B. A. ; Kumthekar, P. ; Wesolowski, R. et al. / Phase I, open-label ascending dose trial of anti-CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti-PD-1/PD-L1 therapy. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29. pp. viii416-viii417.

@article{dd1ab6a526ab4b868194d41f4b46c969,

title = "Phase I, open-label ascending dose trial of anti-CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti-PD-1/PD-L1 therapy",

author = "Wilky, {B. A.} and P. Kumthekar and R. Wesolowski and Hwang, {J. J.} and Park, {S. I.} and G. Yuan and Dupont, {C. D.} and M. Lim and O. Shebanova and Cuillerot, {J. M.} and E. Dow and W. Ortuzar and Raizer, {Jeffrey J} and E. Drouin and N. Wilson and Gonzalez, {A. M.} and Goldberg, {J. M.} and Buell, {J. S.} and Stein, {R. B.} and H. Youssoufian",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy288.040",

language = "English (US)",

volume = "29",

pages = "viii416--viii417",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

}

Wilky, BA, Kumthekar, P, Wesolowski, R, Hwang, JJ, Park, SI, Yuan, G, Dupont, CD, Lim, M, Shebanova, O, Cuillerot, JM, Dow, E, Ortuzar, W, Raizer, JJ, Drouin, E, Wilson, N, Gonzalez, AM, Goldberg, JM, Buell, JS, Stein, RB & Youssoufian, H 2018, 'Phase I, open-label ascending dose trial of anti-CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti-PD-1/PD-L1 therapy', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii416-viii417. https://doi.org/10.1093/annonc/mdy288.040

Phase I, open-label ascending dose trial of anti-CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti-PD-1/PD-L1 therapy. / Wilky, B. A.; Kumthekar, P.; Wesolowski, R. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii416-viii417.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Phase I, open-label ascending dose trial of anti-CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti-PD-1/PD-L1 therapy

AU - Wilky, B. A.

AU - Kumthekar, P.

AU - Wesolowski, R.

AU - Hwang, J. J.

AU - Park, S. I.

AU - Yuan, G.

AU - Dupont, C. D.

AU - Lim, M.

AU - Shebanova, O.

AU - Cuillerot, J. M.

AU - Dow, E.

AU - Ortuzar, W.

AU - Raizer, Jeffrey J

AU - Drouin, E.

AU - Wilson, N.

AU - Gonzalez, A. M.

AU - Goldberg, J. M.

AU - Buell, J. S.

AU - Stein, R. B.

AU - Youssoufian, H.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081531185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081531185&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy288.040

DO - 10.1093/annonc/mdy288.040

M3 - Article

C2 - 32137043

SN - 0923-7534

VL - 29

SP - viii416-viii417

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Wilky BA, Kumthekar P, Wesolowski R, Hwang JJ, Park SI, Yuan G et al. Phase I, open-label ascending dose trial of anti-CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti-PD-1/PD-L1 therapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii416-viii417. doi: 10.1093/annonc/mdy288.040

Phase I, open-label ascending dose trial of anti-CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti-PD-1/PD-L1 therapy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this